Combination treatment of cancer comprising egfr/her2 inhibitors

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/517 (2006.01) A61K 31/00 (2006.01) A61P 35/00 (2006.01)

Patent

CA 2629249

The invention relates to a therapy of cancer comprising co-administration to a person in need of such treatment and/or co-treatment of a person in need of such treatment with effective amounts of: (1) a compound 1 of formula (I), wherein the groups Ra to Rd have the meanings given in the claims and specification; and (2) at least a further chemotherapeutic agent 2; optionally in combination with radiotherapy, radio-immunotherapy and/or tumour resection by surgery, furthermore, the invention relates to corresponding medicaments and the preparation thereof.

L'invention concerne un traitement du cancer comprenant la co-administration à une personne nécessitant un tel traitement et/ou le co-traitement d'une personne nécessitant un tel traitement avec des quantité efficaces : (1) d'une composé 1 représenté par la formule (I), dans laquelle les groupes Ra à Rd ont les significations données dans les revendications et la description ; et (2) d'au moins un agent chimiothérapeutique 2 ; éventuellement combiné à un traitement radiothérapeutique, à un traitement radio-immunothérapeutique et/ou à une résection chirurgicale d'une tumeur. L'invention concerne également des médicaments correspondants ainsi que leur préparation.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Combination treatment of cancer comprising egfr/her2 inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combination treatment of cancer comprising egfr/her2 inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination treatment of cancer comprising egfr/her2 inhibitors will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1395036

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.